Publications, Pharmaceutical

Developing a Dry Powder Formulation for Aptar Pharma Prohaler®

Aptar Pharma Prohaler® is a novel, high performance, multidose dry powder inhaler device with a patient-centric design developed to promote patient compliance.

This paper describes the optimization of a model formulation for Prohaler® via manipulation of the concentration of fine lactose and the inclusion of a force control agent, to reduce the strength of interparticle forces and promote dose deaggregation. The relationship between formulation composition and dissolution profile was also investigated. The inclusion of a force control agent was shown to be highly beneficial in promoting aerosolization, resulting in a higher fine particle mass and a finer mass median aerodynamic diameter. This effect was robust with respect to lactose fine concentration which in the absence of a force control agent was also observed to correlate positively with fine particle mass. Consideration of the use of force control agents is highly recommended when developing formulations for Prohaler®.

Download Publication
8 May 2021

Learn more about Prohaler®

Find Out More

This Might Also Be of Interest

10 Jun 2020

Developing in vitro dissolution tests for orally inhaled drug products

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 Jun 2020

Aptar Pharma expert Q&A on digital health and connected drug delivery

Publications, Pharmaceutical, Brand Differentiation, Product Solutions, Innovation & Insights, Device Innovations

Read More
26 May 2020

Aptar Pharma discusses Article 117 of the Medical Device Regulations

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
12 May 2020

Drug Delivery Systems & Services for Lifecycle Management of Crisis Medications ...

Webinars, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation

Read More
1 14 15 16 17 18 19
Back To Top